Most people on Ozempic lose between 6% and 7% of their body weight when using it at its approved doses for type 2 diabetes. For someone who weighs 250 pounds, that works out to roughly 15 to 18 pounds. The results vary widely, though, and about one in four people don’t respond meaningfully to the drug at all.
Those numbers are lower than what you’ll see in many headlines, and the reason matters: Ozempic is technically a diabetes medication with a maximum dose of 2 mg. Its sister drug Wegovy, which uses the same active ingredient at a higher dose (2.4 mg) and is approved specifically for weight loss, produces an average of about 15% body weight reduction. Many people prescribed Ozempic “off-label” for weight loss are getting a lower dose than what was tested in the blockbuster weight loss trials.
What the Clinical Trials Found
The clearest picture of semaglutide’s weight loss potential comes from the STEP 1 trial, which tested the 2.4 mg dose (the Wegovy dose) in 1,306 people with obesity over 68 weeks. Participants lost an average of 14.9% of their body weight, compared to just 2.4% in the placebo group. That’s a meaningful difference, but again, this was the higher dose.
At Ozempic’s doses, the numbers are more modest. In the SUSTAIN FORTE trial, which compared the 1.0 mg and 2.0 mg doses in people with type 2 diabetes over 40 weeks, the 2.0 mg group lost an average of 6.9 kg (about 15 pounds) and the 1.0 mg group lost 6.0 kg (about 13 pounds). The difference between the two doses was real but not dramatic.
A Realistic Month-by-Month Timeline
Ozempic isn’t prescribed at full dose from day one. You start at 0.25 mg and gradually increase over several months, which means weight loss in the first few weeks is slow. During the first three months of dose escalation, most people lose somewhere between 5% and 10% of their body weight as appetite suppression kicks in and eating patterns shift.
Months four through six tend to be when the most noticeable changes happen, as you reach your maintenance dose and the drug’s full appetite-reducing effects settle in. By months six through nine, many people hit a plateau as the body adjusts to its new weight. This doesn’t mean the drug stopped working. It means you’ve reached a new equilibrium, and maintaining that lower weight is itself an active effect of the medication.
Why Some People Lose Very Little
Not everyone responds to Ozempic. Clinical trials funded by the drug’s manufacturer found that up to 23% of participants were non-responders, typically defined as losing less than 5% of body weight after three months on a GLP-1 drug. Real-world data suggest the rate could be as high as one in four patients.
The reasons aren’t fully understood, but individual biology plays a significant role. People vary in how strongly their brain responds to the drug’s appetite signals, how much their stomach emptying slows, and how their metabolism adapts. If you’ve been on Ozempic for three months at an adequate dose and haven’t lost at least 5% of your starting weight, that’s a reasonable point to reassess the approach with your prescriber.
How It Actually Reduces Weight
Semaglutide mimics a gut hormone your body naturally releases after eating. This hormone signals your brain to reduce hunger and tells your stomach to empty more slowly, so you feel full longer after meals. The net effect is that most people simply eat less without feeling like they’re fighting constant cravings.
Interestingly, research from Monell Chemical Senses Center found that semaglutide changes how the brain’s reward system responds to food. The drug increased activity in dopamine-producing neurons during actual eating but didn’t change the response to food cues like seeing or smelling a meal. In practical terms, this means you can still enjoy food when you eat it, but the anticipatory pull toward food between meals weakens. That shift is a big part of why people describe feeling “food quiet” on the medication.
Ozempic vs. Wegovy vs. Tirzepatide
Since all three drugs come up in weight loss conversations, the differences in expected results are worth knowing. Ozempic maxes out at 2 mg and produces roughly 6% to 7% weight loss in its approved population. Wegovy uses the same molecule at up to 2.4 mg and averages about 15% weight loss in people using it for obesity.
Tirzepatide (sold as Mounjaro for diabetes and Zepbound for weight loss) works on two gut hormones instead of one, and the results reflect that. In the SURMOUNT-5 trial, which directly compared the two drugs over 72 weeks, people on tirzepatide lost an average of 20.2% of their body weight versus 13.7% on semaglutide. That translated to about 50 pounds lost on tirzepatide compared to 33 pounds on semaglutide. Nearly 65% of tirzepatide users lost at least 15% of their body weight, compared to 40% on semaglutide.
What Happens When You Stop
This is the part many people don’t hear about upfront. A systematic review published in The Lancet’s eClinicalMedicine found that at one year after stopping semaglutide, people had regained 60% of the weight they lost during treatment. The trajectory doesn’t stop there: the analysis estimated that weight regain eventually plateaus at about 75% of the lost weight.
So if you lost 30 pounds on Ozempic and then stopped, you could expect to regain roughly 18 pounds within the first year and potentially 22 to 23 pounds over the longer term. This doesn’t mean the drug “failed.” It means semaglutide manages weight the way blood pressure medication manages blood pressure: the effect depends on continued use. Most prescribers now frame these medications as long-term or indefinite treatments rather than short courses.
Setting Realistic Expectations
If you’re taking Ozempic specifically (not Wegovy), expect weight loss in the range of 6% to 7% of your body weight at maintenance doses, with some people losing more and roughly a quarter losing less than 5%. The higher-dose formulation approved for weight management produces roughly double that. Either way, results take months to fully develop, tend to plateau between six and nine months, and depend on continued use to maintain.
The most important number isn’t a percentage from a clinical trial. It’s whether the weight loss you experience is enough to improve the health markers that matter to you, whether that’s blood sugar control, blood pressure, joint pain, or energy levels. Even a 5% to 10% reduction in body weight produces measurable improvements in metabolic health for most people.